Novo Nordisk’s European Reimbursement Milestone and Pipeline Advances Offer a Dual Cue for Skeptical Markets
Veröffentlicht: 03.06.2026 um 08:51 Uhr, Redaktion boerse-global.de
France is set to become the first EU country to reimburse the weight-loss drugs Wegovy and Mounjaro from June 15, a move that could reshape the European obesity market. The decision lands at a critical juncture for Novo Nordisk, which also cleared a major regulatory hurdle last month and is about to unveil pivotal clinical data that may determine whether the stock’s dramatic valuation compression over the past year is justified or overdone.
France Targets a Million Patients as Costs Capped at €100 Million
Under the French social security system, patients with a body mass index of 35 or above and at least one comorbidity, or a BMI of 40 or higher, will qualify for reimbursement. Although the official coverage rate is 65%, practically all eligible patients are expected to be fully covered because common comorbidities such as hypertension or diabetes automatically meet the criteria. The health ministry estimates full uptake would cost the state roughly €100 million annually, targeting around one million patients. Initially, only specialists at obesity centres, endocrinologists and diabetologists can prescribe; general practitioners may write follow-up prescriptions.
CHMP Endorses Two New Wegovy Formats
The European Medicines Agency’s human medicines committee recommended approval of two new Wegovy variants on May 22. First, a once-daily 25 mg oral semaglutide tablet — the first oral GLP-1 formulation the committee has endorsed for weight management. In the OASIS-4 trial, patients achieved an average weight loss of 16.6%, comparable to the injectable version, with one in three losing more than 20%. Second, the committee backed a higher-dose injectable pen delivering 7.2 mg; the STEP-UP study recorded a mean weight loss of 20.7%. European Commission approval is considered a formality. Novo Nordisk targets an EU launch of Wegovy 7.2 mg in the third quarter of 2026, while the oral tablet is slated for select ex-US markets in the second half of the year.
US Momentum Puts the Opportunity in Perspective
The scale of the market is already visible across the Atlantic. In the first quarter of 2026, 1.3 million prescriptions were written for the Wegovy tablet in the US, generating quarterly revenue of 2.3 billion Danish kroner. A clinical edge: the tablet carries no drug-drug interaction restrictions on its label. Meanwhile, the company has also launched a reformulated oral semaglutide under the Ozempic brand in the US for type 2 diabetes, available in 1.5 mg, 4 mg and 9 mg strengths — bioequivalent to the previous Rybelsus tablets but in a smaller pill size. A higher 25 mg oral variant remains under FDA review, with a decision expected by the end of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buyback Programme Gathers Pace as Valuation Hits Multi-Year Lows
While the pipeline advances, management is actively repurchasing shares. The overall buyback programme authorises up to 15 billion kroner over twelve months from February 2026. By May 29, the company had bought back 17.9 million B-shares at an average price of 263.47 kroner, worth almost 4.7 billion kroner. Daily purchases have been running at roughly 210,000 shares; on May 29, Novo Nordisk bought exactly that number at 293.42 kroner per share, for a daily outlay of 61.6 million kroner. The current tranche runs until February 2027 with a maximum volume of about 11.2 billion kroner.
Yet the market remains unconvinced. The stock closed at €36.84, nearly 47% below its 52-week high of €70.13 and 42% lower than a year ago. At a price-earnings ratio of roughly 10.3, valuation has slumped from the heady multiples of 2024. The RSI of 71.6 suggests short-term overbought conditions after a recovery from the March 2026 low of €30.48, but the broader narrative of intensifying competition in the GLP-1 and obesity space continues to weigh. The dividend for the 2025 financial year was 11.70 kroner per share.
CagriSema Data and an Investor Day Loom in New Orleans
All eyes now turn to the American Diabetes Association’s annual scientific sessions, running from June 5 to 8 in New Orleans. Novo Nordisk will present around 40 abstracts, headlined by phase 3 data from the REIMAGINE 1, 2 and 3 studies for CagriSema — a fixed combination of semaglutide and the amylin analogue cagrilintide for type 2 diabetes, obesity and weight management. Additionally, phase 2 results for Zenagamtide, a once-weekly injectable GLP-1/amylin candidate, will be disclosed. On June 7, management hosts an R&D investor day with a live webcast, where it is expected to provide more concrete guidance on the CagriSema approval timeline. An FDA decision on CagriSema is anticipated in the fourth quarter of 2026.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A Softer Outlook for 2026 Keeps Caution in Play
Despite the regulatory and pipeline progress, the company’s own guidance for the current year remains muted. Novo Nordisk expects adjusted revenue and operating profit to decline by four to twelve percent in constant currencies, stripping out the impact of the US 340B drug pricing programme. Robust demand is offset by structural headwinds — a balancing act that leaves the stock’s trajectory hanging on whether the ADA data can reignite investor confidence in the long-term growth story.
Ad
Novo Nordisk Stock: New Analysis - 3 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
